Interestingly, the administration of sacubitril, a neprilysin-inhibitor, in combination with valsartan, an angiotensin I receptor antagonist, led to a significant reduction in hepatic fibrosis and portal hypertension in mice [45]. This evidence concerns the gene MME and liver disorder.